Impact of Water- and Lipid-Soluble Statins on Nonculprit Lesions in Patients with Acute Coronary Syndrome

• Ishikawa Yu

  Division of Cardiology, Department of Internal Medicine, Iwate Medical University

• Itoh Tomonori

  Division of Cardiology, Department of Internal Medicine, Iwate Medical University

• Satoh Mamoru

  Department of Internal Medicine, Division of Cardiovascular Medicine, Nephrology and Endocrinology, Iwate Medical University

• Fusazaki Tetsuya

  Division of Cardiology, Department of Internal Medicine, Iwate Medical University

• Sugawara Shoma

  Division of Cardiology, Department of Internal Medicine, Iwate Medical University

• Nakajima Satoshi

  Division of Cardiology, Department of Internal Medicine, Iwate Medical University

• Nakamura Motoyuki

  Department of Internal Medicine, Division of Cardiovascular Medicine, Nephrology and Endocrinology, Iwate Medical University

• Morino Yoshihiro

  Division of Cardiology, Department of Internal Medicine, Iwate Medical University

Bibliographic Information

Other Title

• A Prospective Randomized Trial

Abstract

Statins can be differentiated into two types, based on their solubility, which have potentially differing effects on the coronary artery wall. However, suspected differences in statins' effects on plaque composition have not been systemically investigated. Sixty-seven patients with acute coronary syndrome (ACS) were randomly assigned to either atorvastatin (10 mg/day) or rosuvastatin (2.5 mg/day). Intravascular ultrasound (IVUS) and integrated backscatter (IB)-IVUS, an established tool to quantify each plaque's components, were performed immediately after emergent percutaneous coronary intervention (PCI). Follow-up IVUS was performed between 6 and 12 months after PCI. Serial changes in serum lipid profiles and plaque composition volumes were compared between the two groups. Thirty-five patients were eligible for serial IB-IVUS analyses. The mean low-density lipoprotein-cholesterol level significantly decreased in the atorvastatin and rosuvastatin groups (P < 0.001); plaque volumes were also significantly reduced from 82.0 ± 46.2 to 74.9 ± 41.3 mm³ (P = 0.01) and from 74.7 ± 35.3 to 67.7 ± 27.0 mm³ (P = 0.02), respectively. IB-IVUS revealed a significant reduction in fibrous volume from 33.8 ± 20.0 to 27.5 ± 14.9 mm³ (P < 0.01) and from 29.6 ± 13.6 to 24.8 ± 7.6 mm³ (P < 0.05), respectively; however, significant changes were not noted in the volume of the lipid pool for the atorvastatin group and the rosuvastatin group, respectively. Water- and lipid-soluble statins may be similarly effective in reducing coronary plaques in patients with ACS as judged qualitatively and quantitatively. Further study is needed to determine whether differences between water- and lipid-soluble statins affect plaque components.

Journal

• International Heart Journal

  International Heart Journal 59 (1), 27-34, 2018

  International Heart Journal Association

Keywords

• Statin therapy
• Plaque composition
• IB-IVUS

Details

• CRID: 1390001205226480896
• NII Article ID: 130006321384
• DOI: 10.1536/ihj.16-587
• ISSN: 13493299
• ISSN: 13492365
• PubMed: 29279527
• Web Site: https://www.jstage.jst.go.jp/article/ihj/59/1/59_16-587/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2019085625
• Text Lang: en
• Data Source:
  • JaLC
  • Crossref
  • PubMed
  • CiNii Articles
• Abstract License Flag: Disallowed